Buy / Hold Stocks

[gfp927z]

>>> Stryker Corporation (NYSE:SYK) - Number of Hedge Fund Holders: 47

https://finance.yahoo.com/news/14-best-robotics-stocks-buy-194148400.html

Stryker Corporation (NYSE:SYK) is a medical technology company operating in two segments – MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment specializes in implants for hip and knee joint replacements, trauma, and extremities surgeries, as well as spinal implant products. The MedSurg and Neurotechnology segment provides a range of medical devices and products for various medical specialties, including surgical equipment, navigation systems, emergency medical equipment, and neurotechnology products for minimally invasive endovascular techniques and brain surgeries. Stryker Corporation (NYSE:SYK) is one of the best robotics stocks to invest in.

On January 30, Stryker Corporation (NYSE:SYK) reported a Q4 non-GAAP EPS of $3.46 and a revenue of $5.8 billion, outperforming $0.19 and $200 million, respectively. Terry Smith’s Fundsmith LLP is the leading stakeholder of the company, with 5.5 million shares worth $1.5 billion.

Baron Health Care Fund stated the following regarding Stryker Corporation (NYSE:SYK) in its fourth quarter 2023 investor letter:

“We initiated a position in Stryker Corporation (NYSE:SYK) during the quarter. Stryker is a large diversified medical device company with two business segments: (1) MedSurg and Neurotechnology, and (2) Orthopedics and Spine. The stock sold off during the quarter along with many other medical device stocks because of concerns about the impact of GLP-1 weight loss medicines on their business (lol). Specific to Stryker, the concern was that weight loss would reduce demand for hip and knee implant procedures because obesity is one factor that drives osteoarthritis. We think this concern was overstated and saw the sell-off as an opportunity to buy a high-quality growth company at a reasonable valuation. We think Stryker is well positioned with its broad product portfolio to benefit from the trend of more orthopedic and other medical procedures moving from the hospital to ambulatory surgery centers. The company also has several new product launches coming up that should drive growth. At its recent Investor Day, management provided long-term financial goals including organic sales growth at the high end of the medical technology industry and double-digit EPS growth.”

<<<



---